Breakthrough study finds that hemogenic endothelial cells in fetal lungs contribute to the formation of blood cells
A newly-released study by Boston Medical Center (BMC) and Boston University’s Center for Regenerative Medicine (CReM) found that the fetal lung is a potential source of hemogenic endothelial cells (HECs) that have the capacity to make blood. The findings broaden the understanding of where and how blood forms, which has the potential to enhance the treatment of blood-related diseases such as leukemia and lymphoma. Previously, no lung HECs had ever been detected.
“Our findings show that hemogenic endothelium, which was previously thought to be restricted to a very early window of fetal development and found only in hematopoietic tissue, is present in the fetal lung,” said lead author Anthony Yeung, MD, PhD candidate of Boston Medical Center and Boston University’s Center for Regenerative Medicine.
HECs are a rare sub-population of vascular cells that make up a small percentage of the developing embryo and were commonly thought to exist in only a small window of time during gestation. These cells, which drive the initial formation of all blood types, were thought to be primarily limited to the aorta gonad mesonephros (AGM). The new study found HECs in the lungs at much later stages of development, suggesting that the lungs play a greater role in blood development than previously known.
“Although our blood and how it forms has been studied for centuries, these findings make us question what we know and tell us that this process is much more complex and elegant than previously thought,” said senior author George J. Murphy, PhD, co-founder of CReM and Associate Professor of Medicine in the Division of Hematology-Oncology at Boston University Chobanian & Avedisian School of Medicine.
Potential for Novel Therapies
Researchers are optimistic that their findings will be important in the development of novel methods to produce blood stem cells that can be utilized for cellular therapies, such as bone marrow transplantation. Currently, scientists are unable to robustly produce and maintain blood stem cells in culture due to our incomplete understanding of all the important molecular processes that are necessary to make a fully functional blood stem cell. Gaining a better understanding of where and how blood cells form gives researchers a better understanding of how to produce blood stem cells that can be used in future treatments.
“This study helps us to better understand how the location and timing of blood development impacts our overall health and development,” Yeung said. “We hope that our work will add to the growing body of knowledge about blood development that will be utilized towards the creation of novel therapies for various types of hematological diseases and cancers.”
The full study was published today in “Blood Advances” and can be located
The Center for Regenerative Medicine (CReM) is a joint effort between Boston University and Boston Medical Center that brings together nine principal investigators who address various aspects of developmental biology, stem cells, regeneration and injury, cell lineage specification and disease modeling with a major focus on induced Pluripotent Stem Cells or iPSCs. You can learn more about the CReM here.
###
About Boston Medical Center
Boston Medical Center models a new kind of excellence in healthcare, where innovative and equitable care empowers all patients to thrive. We combine world-class clinicians and cutting-edge treatments with compassionate, quality care that extends beyond our walls. As an award-winning health equity leader, our diverse clinicians and staff interrogate racial disparities in care and partner with our community to dismantle systemic inequities. And as a national leader in research and the teaching affiliate for Boston University Chobanian & Avedisian School of Medicine, we’re driving the future of care.